BioLife Solutions (BLFS) Receives Media Sentiment Score of 0.15
Media stories about BioLife Solutions (NASDAQ:BLFS) have trended somewhat positive on Monday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. BioLife Solutions earned a news sentiment score of 0.15 on Accern’s scale. Accern also gave news stories about the medical equipment provider an impact score of 48.2938891644322 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the news stories that may have effected Accern Sentiment’s scoring:
- BioLife : Kolon Life Science Launches Osteoarthritis Drug Invossa in Korea (4-traders.com)
- Brokerages Expect BioLife Solutions, Inc. (BLFS) to Post ($0.07) Earnings Per Share (americanbankingnews.com)
- Stock Gaps Up Recap as of Friday – JCP, CREG, HTZ, OMER, AMDA, BLFS, FFHL (fxpips.com)
- Edited Transcript of BLFS earnings conference call or presentation 9-Nov-17 9:30pm GMT (finance.yahoo.com)
Separately, Maxim Group lifted their price target on BioLife Solutions from $7.00 to $8.00 and gave the company a “buy” rating in a report on Friday, November 10th.
BioLife Solutions (NASDAQ:BLFS) opened at $5.92 on Monday. BioLife Solutions has a fifty-two week low of $1.50 and a fifty-two week high of $7.53.
BioLife Solutions (NASDAQ:BLFS) last announced its quarterly earnings results on Thursday, November 9th. The medical equipment provider reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.06) by $0.03. BioLife Solutions had a negative return on equity of 49.92% and a negative net margin of 52.10%. The business had revenue of $2.96 million for the quarter, compared to the consensus estimate of $2.60 million. equities analysts forecast that BioLife Solutions will post -0.21 EPS for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This story was first reported by Watch List News and is the property of of Watch List News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.watchlistnews.com/biolife-solutions-blfs-receives-media-sentiment-score-of-0-15/1715185.html.
BioLife Solutions Company Profile
BioLife Solutions, Inc (BioLife) is engaged in the developing, manufacturing and marketing a portfolio of biopreservation tools and services for cells, tissues and organs, including clinical grade cell and tissue hypothermic storage and cryopreservation freeze media and a related cloud hosted biologistics cold chain management application for shippers.
Receive News & Ratings for BioLife Solutions Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.